Pulmonary Cell News Volume 3.11 | Mar 27 2014

A Fine-Tuned Interaction between the Trimeric Autotransporter Haemophilus Surface Fibrils and Vitronectin Leads to Serum Resistance and Adherence to Respiratory Epithelial Cells
Researchers studied in detail the interaction between Haemophilus surface fibrils and vitronectin and its role in inhibition of membrane attack complex formation and invasion of lung epithelial cells. [Infect Immun] Abstract

Receptor Interacting Protein-2 Plays a Critical Role in Human Lung Epithelial Cells Survival in Response to Fas-Induced Cell-Death
Human lung epithelial cells were induced to undergo cell death in response to the Fas agonist antibody CH11 with and without manipulation of endogenous receptor interacting protein-2 concentrations. Scientists showed that CH11 increases lung epithelial cell death in a dose-dependent manner as determined by LDH release and nuclear condensation. [PLoS One] Full Article

Curcumin and Vitamin E Protect against Adverse Effects of Benzo[a]pyrene in Lung Epithelial Cells
Researchers investigated the adverse effects of benzo[a]pyrene (BaP) on normal human lung epithelial cells, the potential protective effects of curcumin and vitamin E against BaP-induced cellular damage, and the molecular mechanisms of action. [PLoS One] Full Article

LUNG CANCER

Cancer-Associated Fibroblasts Regulate the Plasticity of Lung Cancer Stemness via Paracrine Signaling
Researchers established a sustainable primary culture of Oct3/4(+)/Nanog(+) lung cancer stem cells fed with CD90(+) cancer-associated fibroblasts to further advance knowledge of preserving stem cells in the tumor microenvironment. [Nat Commun] Abstract

The Novel miR-9500 Regulates the Proliferation and Migration of Human Lung Cancer Cells by Targeting Akt1
The overexpression of miR-9500 inhibited cell proliferation and the expression of cell cycle-related proteins. Likewise, the overexpression of miR-9500 impeded cell migration in human lung cancer cells. [Cell Death Differ] Abstract

Synergistic Action by Multi-Targeting Compounds Produces a Potent Compound Combination for Human NSCLC Both In Vitro and In Vivo
By screening a collection of one hundred combinations of thiazolidinone compounds, scientists identified one combination that synergistically inhibited the growth of H460 and H460/TaxR cells and tumor growth in H460/TaxR xenograft mice. [Cell Death Dis] Full Article

Celastrol Induces Apoptosis in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells via Caspases-Dependent Pathways and Hsp90 Client Protein Degradation
Scientists examined the potency of celastrol in three different non-small cell lung cancer (NSCLC) cell lines. They explored its treatment mechanism in two gefitinib-resistant NSCLC cell lines. Their data demonstrated that celastrol exerted its apoptotic effect in a dose- and time-dependent manner. [Molecules]
Abstract | Download Full Article

Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
Researchers found that suppression of the ERBB3 receptor tyrosine kinase sensitizes KRAS mutant lung and colon cancer cells to MEK inhibitors. [Cell Rep] Full Article | Graphical Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

From our sponsor:
Looking for ALDH⁺ cancer stem cells? Watch a video to see how ALDEFLUOR^TM can help.

ARIAD Announces Initiation of Pivotal Phase II ALTA Trial of AP26113 in Patients with Non-Small Cell Lung Cancer
ARIAD Pharmaceuticals, Inc. announced the initiation of a pivotal global Phase II trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer who were previously treated with crizotinib. [ARIAD Pharmaceuticals, Inc.] Press Release

Pfizer Reports Positive Phase III Study Outcome of XALKORI® (crizotinib) Compared to Chemotherapy in Previously Untreated Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Pfizer Inc. announced that PROFILE 1014, a Phase III study of anaplastic lymphoma kinase (ALK) inhibitor XALKORI^® (crizotinib), met its primary objective of significantly prolonging progression-free survival in previously untreated patients with ALK-positive advanced non-squamous NSCLC when compared to standard platinum-based chemotherapy regimens. [Pfizer, Inc.] Press Release

$4.25 Million Grant Awarded to Rutgers Cancer Institute of New Jersey and University of Wisconsin Carbone Cancer Center to Develop Innovative Clinical Trials
Precision medicine, or the movement to ‘personalize’ cancer treatments, has grown significantly over the past few years, with researchers from large universities and cancer centers from across the nation making advances in identifying targeted therapies and understanding what drives them. Aiming to further build on that momentum with the development of innovative early-phase clinical trials examining genomic and therapeutic biomarkers is Robert S. DiPaola. [Rutgers Cancer Institute of New Jersey] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the pulmonary cell community.

Research Project Leader – Next Generation Lung Cancer Diagnostics (BIOBASE)

Postdoctoral Scholar – Mechanisms of Pathologic Mucus Gel Formation in Diseases of the Lung (University of California, San Francisco)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Postdoctoral Position – Pulmonary Research (Cedars-Sinai Medical Center)

Junior Research Group Leader – Stem Cell Based Therapies for Lung Diseases (Hannover Medical School)

Postdoctoral Position – Novel Therapeutic Approaches to the Treatment of Lung Cancer (Sloan Kettering Institute)

PhD Studentships in Pulmonary Medicine (University of Giessen and Marburg Lung Center)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.